XML 53 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Balance Sheet Details (Tables)
9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Short Term Marketable Securities, Available for Sale
Short-Term Marketable Securities
Short-term marketable securities, consisting of equity securities and debt securities, were as follows as of the dates indicated.
 
September 30, 2019
(In millions)
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
Debt securities, available for sale:
 
 
 
 
 
 
 
U.S. government agencies
$
698.6

 
$
0.4

 
$

 
$
699.0

Commercial paper
277.9

 
0.1

 
(0.1
)
 
277.9

Corporate debt
57.4

 

 

 
57.4

Total debt securities, available for sale
1,033.9

 
0.5

 
(0.1
)
 
1,034.3

 
 
 
 
 
 
 
 
Total marketable securities
$
1,033.9

 
$
0.5

 
$
(0.1
)
 
$
1,034.3


 
December 31, 2018
(In millions)
Cost or Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
Equity investment in Tandem Diabetes Care, Inc.
$
2.0

 
$
36.0

 
$

 
$
38.0

 
 
 
 
 
 
 
 
Debt securities, available for sale:
 
 
 
 
 
 
 
U.S. government agencies
173.2

 

 
(0.1
)
 
173.1

Commercial paper
36.2

 

 

 
36.2

Corporate debt
1.3

 

 

 
1.3

Total debt securities, available for sale
210.7

 

 
(0.1
)
 
210.6

 
 
 
 
 
 
 
 
Total marketable securities
$
212.7

 
$
36.0

 
$
(0.1
)
 
$
248.6


Net Gain Recognized on Equity Securities
The following table reconciles the net gain recognized on equity securities during the three and nine months ended September 30, 2019 and 2018 to the unrealized gain recognized during the periods on equity securities still held at the reporting date. We sold the equity investment in Tandem Diabetes Care, Inc. that we held as of December 31, 2018 during the first quarter of 2019 and did not have any outstanding equity securities as of September 30, 2019.
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
(In millions)
2019
 
2018
 
2019
 
2018
Net gains and losses recognized during the period on equity securities
$

 
$
34.9

 
$
(4.2
)
 
$
85.0

Less: Net gains and losses recognized during the period on equity securities sold during the period

 
(14.1
)
 
4.2

 
(44.2
)
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$

 
$
20.8

 
$

 
$
40.8


Inventory
Inventory
(In millions)
September 30, 2019
 
December 31, 2018
Raw materials
$
57.9

 
$
30.8

Work-in-process
8.2

 
11.2

Finished goods
54.3

 
28.7

Total inventory
$
120.4

 
$
70.7


Property, Plant and Equipment
Property and Equipment
(In millions)
September 30, 2019
 
December 31, 2018
Building and land
$
15.5

 
$
6.0

Furniture and fixtures
12.2

 
9.0

Computer software and hardware
32.8

 
29.2

Machinery and equipment
97.5

 
80.7

Leasehold improvements
96.6

 
80.7

Construction in progress
148.0

 
57.3

Total cost
402.6

 
262.9

Less accumulated depreciation and amortization
(101.6
)
 
(79.8
)
Total property and equipment, net
$
301.0

 
$
183.1


Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities
(In millions)
September 30, 2019
 
December 31, 2018
Accounts payable trade
$
101.4

 
$
75.5

Accrued tax, audit, and legal fees
20.3

 
11.7

Accrued rebates
74.6

 
36.1

Accrued warranty
7.5

 
6.8

Restructuring reserve
0.7

 

Other accrued liabilities
27.9

 
17.0

Total accounts payable and accrued liabilities
$
232.4

 
$
147.1


Other Liabilities
Other Long-Term Liabilities
(In millions)
September 30, 2019
 
December 31, 2018
Finance lease liabilities
$
14.5

 
$
7.3

Deferred rent

 
9.4

Other liabilities
3.1

 
3.3

Total other long-term liabilities
$
17.6

 
$
20.0